SPY756.50−0.44%QQQ683.64−0.98%BTC/USD72,695.00−1.67%DIA524.91+0.09%GLD360.58−1.26%TLT80.88−0.05%
BenzingaPremium Services
Premium Services
Benzinga Newdesk

Benzinga Newdesk

Benzinga Staff Writer

Articles by Benzinga Newdesk

AcelRx Pharmaceuticals Announces 20-For-1 Reverse Stock Split Effective Tomorrow, Oct. 26
PRO
AcelRx Pharmaceuticals Announces 20-For-1 Reverse Stock Split Effective Tomorrow, Oct. 26
AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced
The Bear Cave Issues Short Report Titled 'Problems at ZoomInfo Technologies (ZI)'
PRO
The Bear Cave Issues Short Report Titled 'Problems at ZoomInfo Technologies (ZI)'
https://thebearcave.substack.com/p/problems-at-zoominfo-technologies?s=r
Goldman Sachs Says Don't Expect 2022 To Look Like 2021, Especially As Monetary Policy Tightens And Fiscal Policy Becomes Less Supportive
PRO
Goldman Sachs Says Don't Expect 2022 To Look Like 2021, Especially As Monetary Policy Tightens And Fiscal Policy Becomes Less Supportive
-Reuters
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved